Novartis Gets US Approval for Zykadia for ALK-Positive NSCLC Patients Unresponsive to Xalkori

Apr 30, 2014

|

Premium

NEW YORK (GenomeWeb) – For patients who have ALK-positive, advanced non-small cell lung cancer tumors and have stopped responding to Pfizer’s Xalkori (crizotinib), the US Food and Drug Administration this week approved a new option from Novartis called Zykadia (ceritinib).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Here We Are Again

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

In the Pink

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

All Tied Up in a Bow

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

This Week in PNAS

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.

Featured White Papers

The Foundry Model is Coming to Molecular Diagnostics, Courtesy of the Semiconductor Industry

Combined Analysis of CNVs and SNVs in Genomic Diagnostics

May

15

Featured Webinar

Reaping the Benefits of Algorithm-Driven Research in Synthetic Biology

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.

Jun

20

Featured Webinar

Expert Tips on Sequencing and Library Prep from the Wellcome Sanger Institute

In this webinar, Michael Quail of the R&D Sequencing team at the Wellcome Trust Sanger Institute will provide an expert perspective on library prep for next-generation sequencing.

Jun

28

Featured Webinar

An Optimized NGS Workflow for Human Metagenomic Analysis

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.

Main menu